Literature DB >> 25544504

IL-17 induces radiation resistance of B lymphoma cells by suppressing p53 expression and thereby inhibiting irradiation-triggered apoptosis.

Qingshan Li1, Xin Xu2, Weijie Zhong2, Qinghua Du3, Bizhen Yu3, Huabao Xiong4.   

Abstract

p53 is a well-known tumor suppressor. However, the regulatory mechanism(s) for p53 expression in B lymphoma cells, and the possible role of p53 in the development of the radioresistance in tumor cells are largely unknown. A human B lymphoma cell line, Karpas1106 (k1106), was used as a model of radioresistance. Apoptosis of k1106 cells was determined using flow cytometry. Expression of p53 was assessed using real time RT-PCR and western blotting. The results showed that irradiation at 8 Gy induced apoptosis in up to 40% of k1106 cells. At the same time, the irradiation markedly increased IL-6 production of the k1106 cells. When k1106 cells were cocultured with regulatory T cells (Tregs) and irradiated, the rate of apoptotic k1106 cells was significantly reduced, indicating an acquired resistance to irradiation. IL-6 derived from the irradiation-treated k1106 cells induced IL-17 expression in Tregs. The IL-17(+)Foxp3(+) T cells suppressed p53 expression in k1106 cells. Collectively, irradiated k1106 cells induce the expression of IL-17 in Tregs, which interferes with the expression of p53 protein in k1106 cells and thereby represses irradiation-triggered apoptosis in k1106 cells.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25544504      PMCID: PMC4654313          DOI: 10.1038/cmi.2014.122

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN: 1672-7681            Impact factor:   11.530


  30 in total

Review 1.  Diagnostic techniques and therapeutic challenges in patients with TP53 dysfunctional chronic lymphocytic leukemia.

Authors:  Giles Best; Philip Thompson; Constantine S Tam
Journal:  Leuk Lymphoma       Date:  2012-05-31

Review 2.  High-dose therapy followed by stem cell transplantation in Hodgkin's lymphoma: past and future.

Authors:  Alessandro Isidori; Pier Paolo Piccaluga; Federica Loscocco; Barbara Guiducci; Sara Barulli; Teresa Ricciardi; Paola Picardi; Giuseppe Visani
Journal:  Expert Rev Hematol       Date:  2013-08       Impact factor: 2.929

3.  RAD9 enhances radioresistance of human prostate cancer cells through regulation of ITGB1 protein levels.

Authors:  Constantinos G Broustas; Howard B Lieberman
Journal:  Prostate       Date:  2014-08-11       Impact factor: 4.104

4.  Significance of interleukin-6 signaling in the resistance of pharyngeal cancer to irradiation and the epidermal growth factor receptor inhibitor.

Authors:  Chih-Cheng Chen; Wen-Cheng Chen; Chang-Hsien Lu; Wen-Hung Wang; Paul-Yang Lin; Kuan-Der Lee; Miao-Fen Chen
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-03-15       Impact factor: 7.038

5.  Interleukin-17 may be a valuable serum tumor marker in patients with colorectal carcinoma.

Authors:  G Radosavljevic; B Ljujic; I Jovanovic; Z Srzentic; S Pavlovic; N Zdravkovic; M Milovanovic; D Bankovic; M Knezevic; L J Acimovic; N Arsenijevic
Journal:  Neoplasma       Date:  2010       Impact factor: 2.575

6.  Increased frequencies of T helper type 17 cells in the peripheral blood of patients with acute myeloid leukaemia.

Authors:  C Wu; S Wang; F Wang; Q Chen; S Peng; Y Zhang; J Qian; J Jin; H Xu
Journal:  Clin Exp Immunol       Date:  2009-08-11       Impact factor: 4.330

7.  Risk of secondary cancers from scattered radiation during intensity-modulated radiotherapies for hepatocellular carcinoma.

Authors:  Dong Wook Kim; Kwangzoo Chung; Weon Kuu Chung; Sun Hyun Bae; Dong Oh Shin; Seongeon Hong; Sung Ho Park; Sung-Yong Park; Chae-Seon Hong; Young Kyung Lim; Dongho Shin; Se Byeong Lee; Hyun-ho Lee; Jiwon Sung; Myonggeun Yoon
Journal:  Radiat Oncol       Date:  2014-05-08       Impact factor: 3.481

Review 8.  Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence.

Authors:  Mohit Trikha; Robert Corringham; Bernard Klein; Jean-François Rossi
Journal:  Clin Cancer Res       Date:  2003-10-15       Impact factor: 12.531

Review 9.  Suppression, subversion and escape: the role of regulatory T cells in cancer progression.

Authors:  K Oleinika; R J Nibbs; G J Graham; A R Fraser
Journal:  Clin Exp Immunol       Date:  2013-01       Impact factor: 4.330

10.  Long-term outcomes in patients with early stage nodular lymphocyte-predominant Hodgkin's lymphoma treated with radiotherapy.

Authors:  Abhishek A Solanki; Melissa Horoschak LeMieux; Brian C-H Chiu; Usama Mahmood; Yasmin Hasan; Matthew Koshy
Journal:  PLoS One       Date:  2013-09-18       Impact factor: 3.240

View more
  11 in total

1.  Cholecystokinin attenuates radiation-induced lung cancer cell apoptosis by modulating p53 gene transcription.

Authors:  Yi Han; Chongyu Su; Daping Yu; Shijie Zhou; Xiaoyun Song; Shuku Liu; Ming Qin; Yunsong Li; Ning Xiao; Xiaoqing Cao; Kang Shi; Xu Cheng; Zhidong Liu
Journal:  Am J Transl Res       Date:  2017-02-15       Impact factor: 4.060

2.  Correlation between IL-17A expression in nasopharyngeal carcinoma tissues and cells and pathogenesis of NPC in endemic areas.

Authors:  Li-Xin Wang; Rui-Xia Ma; Ling-Ling Di; Xian-Bing Peng; Zhao-Peng Kang; Sen Zhong
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-08-27       Impact factor: 2.503

Review 3.  Effects of radiation on T regulatory cells in normal states and cancer: mechanisms and clinical implications.

Authors:  Shu Liu; Xiangdong Sun; Jinhua Luo; Hongcheng Zhu; Xi Yang; Qing Guo; Yaqi Song; Xinchen Sun
Journal:  Am J Cancer Res       Date:  2015-10-15       Impact factor: 6.166

4.  Rituximab or irradiation promotes IL-17 secretion and thereby induces resistance to rituximab or irradiation.

Authors:  Weijie Zhong; Qingshan Li
Journal:  Cell Mol Immunol       Date:  2017-11-20       Impact factor: 11.530

5.  Epithelial p53 Status Modifies Stromal-Epithelial Interactions During Basal-Like Breast Carcinogenesis.

Authors:  Ashley M Fuller; Lin Yang; Alina M Hamilton; Jason R Pirone; Amy L Oldenburg; Melissa A Troester
Journal:  J Mammary Gland Biol Neoplasia       Date:  2021-01-13       Impact factor: 2.698

6.  IL-17A Promotes Intracellular Growth of Mycobacterium by Inhibiting Apoptosis of Infected Macrophages.

Authors:  Andrea Cruz; Paula Ludovico; Egidio Torrado; José Bernardo Gama; Jeremy Sousa; Joana Gaifem; Rui Appelberg; Fernando Rodrigues; Andrea M Cooper; Jorge Pedrosa; Margarida Saraiva; António G Castro
Journal:  Front Immunol       Date:  2015-09-30       Impact factor: 7.561

7.  Increased expression of IRF8 in tumor cells inhibits the generation of Th17 cells and predicts unfavorable survival of diffuse large B cell lymphoma patients.

Authors:  Weijie Zhong; Xin Xu; Zhigang Zhu; Qinghua Du; Hong Du; Li Yang; Yanying Ling; Huabao Xiong; Qingshan Li
Journal:  Oncotarget       Date:  2017-07-25

8.  Comparison of time and dose dependent gene expression and affected pathways in primary human fibroblasts after exposure to ionizing radiation.

Authors:  Lara Kim Brackmann; Alicia Poplawski; Caine Lucas Grandt; Heike Schwarz; Thomas Hankeln; Steffen Rapp; Sebastian Zahnreich; Danuta Galetzka; Iris Schmitt; Christian Grad; Lukas Eckhard; Johanna Mirsch; Maria Blettner; Peter Scholz-Kreisel; Moritz Hess; Harald Binder; Heinz Schmidberger; Manuela Marron
Journal:  Mol Med       Date:  2020-09-09       Impact factor: 6.354

9.  MicroRNA-150 enhances radiosensitivity by inhibiting the AKT pathway in NK/T cell lymphoma.

Authors:  Shao Jie Wu; Jun Chen; BingYi Wu; Yu Jue Wang; Kun Yuan Guo
Journal:  J Exp Clin Cancer Res       Date:  2018-01-31

10.  FDG PET/CT parameters and correlations with tumor-absorbed doses in a phase 1 trial of 177Lu-lilotomab satetraxetan for treatment of relapsed non-Hodgkin lymphoma.

Authors:  Ayca Løndalen; Johan Blakkisrud; Mona-Elisabeth Revheim; Ulf Erik Madsbu; Jostein Dahle; Arne Kolstad; Caroline Stokke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-11-16       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.